Enlivex Therapeutics (NASDAQ:ENLV) Rating Increased to Hold at Wall Street Zen

Enlivex Therapeutics (NASDAQ:ENLV) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Several other equities analysts have also issued reports on ENLV. D. Boral Capital reaffirmed a “hold” rating on shares of Enlivex Therapeutics in a report on Monday, November 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enlivex Therapeutics in a research report on Monday, December 29th. Finally, HC Wainwright boosted their price objective on Enlivex Therapeutics from $7.00 to $13.00 and gave the company a “buy” rating in a research note on Monday, January 12th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $13.00.

Enlivex Therapeutics Stock Performance

Shares of Enlivex Therapeutics stock opened at $1.15 on Friday. The company has a fifty day simple moving average of $0.98 and a 200-day simple moving average of $1.03. The stock has a market cap of $272.99 million, a price-to-earnings ratio of -2.09 and a beta of 1.63. Enlivex Therapeutics has a 12-month low of $0.66 and a 12-month high of $2.10.

Institutional Investors Weigh In On Enlivex Therapeutics

Several large investors have recently modified their holdings of the stock. Citizens Financial Group Inc. RI acquired a new position in Enlivex Therapeutics in the 3rd quarter valued at $241,000. Virtu Financial LLC purchased a new stake in shares of Enlivex Therapeutics in the fourth quarter valued at about $33,000. Invesco Ltd. purchased a new stake in shares of Enlivex Therapeutics in the fourth quarter valued at about $43,000. XTX Topco Ltd lifted its position in Enlivex Therapeutics by 44.8% in the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after purchasing an additional 19,132 shares during the period. Finally, Jane Street Group LLC lifted its position in Enlivex Therapeutics by 244.1% in the fourth quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after purchasing an additional 52,553 shares during the period. Hedge funds and other institutional investors own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.